BridgeMD
Compares treatment options for Bruxism
Official title Somatosensory Training Versus Exercise Therapy in Awake Bruxism
ClinicalTrials.gov ID: NCT07336082
What this study is testing
- What it's testing
- Awake bruxism (daytime teeth clenching or jaw tension) is a common condition that can cause jaw pain, facial pain, muscle fatigue, and reduced quality of life. Although current treatments often focus on the jaw muscles and posture, recent research suggests that changes in the brain's sensory processing may also play an important role in bruxism-related pain.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45
You may be able to join if
- Adults aged 18 to 45 years
- Clinical diagnosis of awake bruxism confirmed using standardized diagnostic criteria (STAB and DC/TMD Axis I)
- Presence of at least one measurable somatosensory alteration confirmed at baseline using digital and clinical assessments
- Self-reported daytime jaw clenching or parafunctional activity
- Baseline orofacial pain intensity of ≥5/10 on a Visual Analog Scale (VAS)
You likely can't join if
- GCPS Grade IV (high disability level)
- Presence of systemic inflammatory, neurological, or rheumatological disorders
- Diagnosis of severe chronic pain conditions unrelated to bruxism
- Use of occlusal splints or participation in jaw, neck, or facial therapy within the past 3 months
- Psychiatric disorders or cognitive impairment that could interfere with study participation
- Pregnancy, due to potential effects on joint laxity and postural parameters
See the full eligibility criteria
- Adults aged 18 to 45 years
- Clinical diagnosis of awake bruxism confirmed using standardized diagnostic criteria (STAB and DC/TMD Axis I)
- Presence of at least one measurable somatosensory alteration confirmed at baseline using digital and clinical assessments
- Self-reported daytime jaw clenching or parafunctional activity
- Baseline orofacial pain intensity of ≥5/10 on a Visual Analog Scale (VAS)
- Chronic pain graded as GCPS Grades I-III according to DC/TMD Axis II (Turkish validated version)
- Willingness to comply with the study protocol and attend scheduled treatment sessions
- Ability to understand the study procedures and provide written informed consent
- GCPS Grade IV (high disability level)
- Presence of systemic inflammatory, neurological, or rheumatological disorders
- Diagnosis of severe chronic pain conditions unrelated to bruxism
- Use of occlusal splints or participation in jaw, neck, or facial therapy within the past 3 months
- Psychiatric disorders or cognitive impairment that could interfere with study participation
- Pregnancy, due to potential effects on joint laxity and postural parameters
The study team makes the final eligibility decision.
Where it's taking place
- Aydin, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aydin, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.